The FDA proposes removing GLP-1 from the compounding list, and if you take a compounded version of semaglutide or tirzepatide, that headline probably set off some alarm. The details: The FDA proposal targets one specific type of large-scale compounding, not the patient-by-patient pharmacies that most telehealth providers use. This guide walks through exactly what the […]
By Astra Editorial Team
Published:
Updated:
The FDA proposes removing GLP-1 from the compounding list, and if you take a compounded version of semaglutide or tirzepatide, that headline probably set off some alarm. The details: The FDA proposal targets one specific type of large-scale compounding, not the patient-by-patient pharmacies that most telehealth providers use. This guide walks through exactly what the FDA proposed, where things stand right now, and what it does and does not mean for your access and your refills.
Quick answer: In April 2026 the FDA proposed keeping semaglutide, tirzepatide, and liraglutide off the 503B bulks list, which would end the large-scale bulk compounding of these GLP-1 drugs. It is not yet a final rule, and the comment period closed July 30, 2026. Patient-specific 503A compounding remains legal, so you can still get a compounded GLP-1 from a licensed 503A pharmacy with a valid prescription.
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying there is no clinical need for large outsourcing facilities to make these drugs from bulk ingredients. Meaning the agency is moving to shut the door on industrial-scale compounding of the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda.
There are two important distinctions when we talk of “compounding”: 503A pharmacy vs 503B pharmacy. Think of these two as different kitchens. One is a 503A pharmacy: a made-to-order kitchen that cooks a single dish for a single named customer who handed over a specific ticket. The other is a 503B outsourcing facility: a factory kitchen that mass-produces the same dish by the thousand so companies can stock shelves and ship at volume.
Both are compounding, but they run under different rules, and this proposal is aimed at only one: the 503B facilities.
In the first place, GLP-1 drugs were never on the 503B “bulks list” that lets the factory kitchen operate. The only thing that made large-scale compounding legal these past few years was a temporary rule that kicks in during an official drug shortage.
When the FDA declared the semaglutide and tirzepatide shortages resolved, that opening closed. This new proposal would keep it closed for good, so that 503B facilities can no longer mass-produce these drugs from bulk ingredients. 503A compounding pharmacies remain untouched.
Astra runs on that framework. Every prescription is patient-specific, filled by VialsRx (a US-licensed 503A pharmacy), and reviewed by a licensed clinician at Wasef Health, PC.
Start your health profile →As of August 2026, this is still a proposal. The comment period ran from May 1 to July 30, 2026, and the FDA has not announced a final decision.
The table below tracks the FDA’s own milestones, but read the right-hand column, because that is where each step actually touched patients.
| Date | FDA milestone | What it meant for patients |
|---|---|---|
| 2022 | Semaglutide and tirzepatide declared in shortage | The cheap compounded versions became widely available |
| 2024 to early 2025 | Shortages declared resolved | The legal basis for that cheap supply started to disappear |
| April 1, 2026 | Drugs confirmed off both the shortage list and the 503B bulks list | Bulk compounders lost their footing; some began winding down |
| April 30, 2026 | Proposal announced to keep the drugs off the 503B bulks list | The plan to close bulk compounding permanently went public |
| May to July 2026 | Public comment period (extended once), closing July 30 | Your last window to weigh in officially passed |
| Pending | FDA reviews comments before a final rule | Bulk access is on notice; individual 503A access continues for now |
No. Even if the proposal is finalized exactly as written, it would end 503B bulk compounding, not all compounding.
The proposal is aimed squarely at 503B outsourcing facilities and the industrial-scale supply that fueled the cheap, mass-marketed compounded products of the last few years. It does not touch 503A patient-specific compounding. A licensed 503A pharmacy can still prepare compounded semaglutide or tirzepatide for an individual patient who has a valid prescription and a documented clinical reason.
That is why the phrase “tightening the rules” would be more apt here instead of “banning.” The FDA has reinforced its position in a few ways at once: it clarified what counts as compounding “essentially a copy” of an approved drug, it proposed the 503B exclusion above, and it warned roughly 30 telehealth firms and compounders marketing compounded GLP-1 products.
Compounded semaglutide and tirzepatide remain legal today through 503A pharmacies with patient-specific prescriptions. Astra was built on that framework from Day 1. Start a 5-minute health profile and a licensed clinician reviews your case.
Start your health profile →Supply and safety. The FDA says that once the brand-name drugs are back in stock, there is no medical reason for factories to keep mass-producing copies, and that some of those copies have hurt people.
As of early 2025, the FDA had logged more than 455 adverse event reports tied to compounded semaglutide and over 320 for compounded tirzepatide, many involving dosing errors from people drawing the wrong amount out of multidose vials, and it has flagged concerns about counterfeit products sold online.
The agency has also been clear on a point that frustrates a lot of patients: under the law, lower cost and better access do not count as a “clinical need”. Affordability, although a persistent concern, is not something the FDA can weigh in this specific decision.
The companies that make Zepbound and Wegovy, Eli Lilly and Novo Nordisk, have also been suing compounders and marketers across the country, so the legal squeeze is coming from two directions at once.
If you use a reputable telehealth provider that fills through a licensed 503A pharmacy, your access to compounded semaglutide and compounded tirzepatide should continue. If your provider relied on bulk 503B supply, you may see changes.
The takeaway is to choose carefully. The providers most exposed to this are the ones that leaned on industrial-scale supply and aggressive marketing, which are also the ones the FDA’s warning letters targeted.
Look for a provider that works with a US-licensed 503A pharmacy, has a licensed clinician review your prescription, uses base-form medication, and prices transparently.
| Provider | Pharmacy model | Clinician review | Notes |
|---|---|---|---|
| Astra | US-licensed 503A | Yes, every prescription | Base-form medication, no hidden fees, free shipping |
| Ivim Health | 503A / 503B | Yes | Adds a monthly membership fee |
| Mochi Health | 503A | Yes | Membership plus medication pricing |
| Henry Meds | 503A | Yes | Not available in all states |
| Eden | 503A | Yes | Membership required |
Whichever provider you choose, a few questions protect you: Which pharmacy fills my prescription, and is it a licensed 503A? Does a licensed clinician review my case? Is this base-form semaglutide or tirzepatide, not a salt form? If a seller cannot answer those clearly, that is your signal to look elsewhere. For more on the model itself, see what is 503A compounding, and if you are new to these drugs, start with what is a GLP-1.
Astra runs on a US-licensed 503A pharmacy with patient-specific prescriptions and licensed clinician review.
Start your health profile Takes about 5 minutes.Not entirely. The FDA’s proposal would end large-scale 503B bulk compounding, but patient-specific 503A compounding remains legal. You can still get a compounded GLP-1 from a licensed 503A pharmacy with a valid prescription.
No. The FDA proposed keeping these drugs off the 503B bulks list, which limits industrial-scale compounding. It is not a final rule yet, and it does not ban all compounding.
Yes, as of August 2026 you can, through a provider that fills your prescription at a licensed 503A pharmacy. It’s the bulk supply route that might be closing, not the individualized one.
For a lot of people, compounded semaglutide has been that alternative, costing a few hundred dollars a month when the brand ran four figures. It still requires a prescription and a licensed pharmacy. Brand-name options have also gotten cheaper through manufacturer self-pay programs.
Compounded semaglutide is usually the cheapest legitimate option for cash-pay patients, followed by compounded tirzepatide. Brand-name self-pay prices have come down too but remain higher.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.